Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

Laquinimod (LAQ) is a new oral immunomodulatory compound that reduces relapse rate, brain atrophy and disability progression in multiple sclerosis (MS). LAQ has well-documented effects on inflammation in the periphery, but little is known about its direct activity within the central nervous system (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brück, Wolfgang, Pförtner, Ramona, Pham, Trinh, Zhang, Jingya, Hayardeny, Liat, Piryatinsky, Victor, Hanisch, Uwe-Karsten, Regen, Tommy, van Rossum, Denise, Brakelmann, Lars, Hagemeier, Karin, Kuhlmann, Tanja, Stadelmann, Christine, John, Gareth R., Kramann, Nadine, Wegner, Christiane
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer-Verlag 2012
Materias:
Original Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3422618/
https://ncbi.nlm.nih.gov/pubmed/22766690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00401-012-1009-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares